

Timothy Heffernan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3912051/publications.pdf>

Version: 2024-02-01

30
papers

4,608
citations

304743

22
h-index

454955

30
g-index

31
all docs

31
docs citations

31
times ranked

9565
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. <i>Nature</i> , 2014, 514, 628-632.	27.8	998
2	Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. <i>Cancer Discovery</i> , 2015, 5, 860-877.	9.4	696
3	An inhibitor of oxidative phosphorylation exploits cancer vulnerability. <i>Nature Medicine</i> , 2018, 24, 1036-1046.	30.7	622
4	Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer. <i>Cell</i> , 2014, 158, 185-197.	28.9	553
5	BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. <i>Cancer Discovery</i> , 2021, 11, 142-157.	9.4	223
6	Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	192
7	Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	161
8	Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. <i>Nature</i> , 2019, 568, 410-414.	27.8	129
9	Efficacy of the combination of MEK and CDK4/6 inhibitors <i>in vitro</i> and <i>in vivo</i> in KRAS mutant colorectal cancer models. <i>Oncotarget</i> , 2016, 7, 39595-39608.	1.8	101
10	Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. <i>Science</i> , 2021, 373, eabj0486.	12.6	99
11	High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. <i>Nature Communications</i> , 2018, 9, 5079.	12.8	91
12	Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2021, 81, 5572-5581.	0.9	75
13	Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. <i>Cancer Cell</i> , 2020, 37, 720-734.e13.	16.8	74
14	Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer. <i>Cancer Research</i> , 2015, 75, 1091-1101.	0.9	68
15	Oncogenic <i>KRAS</i> Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis. <i>Cancer Discovery</i> , 2021, 11, 2094-2111.	9.4	66
16	<i>In Vivo</i> Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype. <i>Cancer Discovery</i> , 2016, 6, 650-663.	9.4	59
17	Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. <i>Nature</i> , 2022, 606, 797-803.	27.8	54
18	Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib. <i>Cancer Research</i> , 2020, 80, 4840-4853.	0.9	49

#	ARTICLE	IF	CITATIONS
19	Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12957-12977.	6.4	48
20	ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	42
21	Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research. <i>Cancers</i> , 2019, 11, 1321.	3.7	34
22	PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. <i>Nature Communications</i> , 2021, 12, 4626.	12.8	31
23	<i>EGFR</i> Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 1395-1407.	7.0	26
24	Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition. <i>Cancer Research</i> , 2021, 81, 4054-4065.	0.9	24
25	Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. <i>Gastroenterology</i> , 2021, 161, 196-210.	1.3	23
26	Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer. <i>Cancers</i> , 2019, 11, 462.	3.7	20
27	Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. <i>Nature Communications</i> , 2021, 12, 6340.	12.8	17
28	Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9888-9911.	6.4	14
29	Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer. <i>Scientific Reports</i> , 2020, 10, 17899.	3.3	9
30	Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in <i>Braf</i> -mutated melanoma. <i>Oncolmmunology</i> , 2021, 10, 1992880.	4.6	7